The objective was to assess the efficacy of coenzyme Q10 as a preventive treatment for migraine headaches. Thirty-two patients (26 women, 6 men) with a history of episodic migraine with or without aura were treated with coenzyme Q10 at a dose of 150 mg per day. Thirty-one of 32 patients completed the study; 61.3% of patients had a greater than 50% reduction in number of days with migraine headache. The average number of days with migraine during the baseline period was 7.34 and this decreased to 2.95 after 3 months of therapy, which was a statistically significant response (P< 0.0001). Mean reduction in migraine frequency after 1 month of treatment was 13.1% and this increased to 55.3% by the end of 3 months. Mean migraine attack frequency was 4.85 during the baseline period and this decreased to 2.81 attacks by the end of the study period, which was a statistically significant response (P< 0.001). There were no side-effects noted with coenzyme Q10. From this open label investigation coenzyme Q10 appears to be a good migraine preventive. Placebo-controlled trials are now necessary to determine the true efficacy of coenzyme Q10 in migraine prevention.
Todd D Rozen, Cleveland Clinic Headache Center, Department of Neurology T33, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. Tel. +2164448265, fax +216 4451696, e-mail RozenT@ccf.org Received 22 October 2001, accepted 4 December 2001
TD Rozen, ML Oshinsky, CA Gebeline, KC Bradley, WB Young, AL Shechter & SD Silberstein Jefferson Headache Center/Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL & Silberstein SD. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002; 22:137-141. London. ISSN 0333-1024